Scholarlink

Introduction <p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure (HF), but their effect on arrhythmias is less clear. Patients with implantable cardioverter-defibrillators (ICDs) are a high risk population for ventricular arrhythmias. However, the effects of SGLT2 inhibitors on ventricular arrhythmias remains a source of debate.</p> Methods <p>We systematically searched PubMed, Scopus, and Cochrane databases from inception to August 19, 2025, for studies evaluating SGLT2 inhibitors and arrhythmic/cardiovascular outcomes. Pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model.</p> Results <p>A total of 1,605 patients were included in our analysis. SGLT2 inhibitors was associated with a significant reduction in the risk of ventricular arrhythmia (RR: 0.38; 95% CI: 0.17 to 0.81; <i>p</i> = 0.01), ventricular tachycardia (RR: 0.60; 95% CI: 0.41 to 0.88; <i>p</i> = 0.009), and supraventricular tachycardia (RR: 0.67; 95% CI: 0.47 to 0.95; <i>p</i> = 0.02). No significant effect was observed on non-sustained VT (RR: 0.94; 95% CI: 0.52 to 1.67; <i>p</i> = 0.83). However, SGLT2 inhibitors were also associated with a significant reduction in ICD shocks (RR: 0.49; 95% CI: 0.38 to 0.64; <i>p</i> &lt; 0.00001) and cardiovascular mortality (RR: 0.39; 95% CI: 0.22 to 0.70; <i>p</i> = 0.002).</p> Conclusion <p>In ICD patients, SGLT2 inhibitor therapy significantly reduced ventricular arrhythmias, discrete sustained VT, and SVT, with secondary analyses suggesting fewer ICD shocks and reduction in CV mortality in the patients with ICD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of sodium glucose cotransporter-2 inhibitors on ventricular arrhythmia in patients with implantable cardioverter-defibrillators: a meta analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月28日

查看全文
  • Mayank Jha,
  • Danielle Serafim Howell,
  • Oybek Nazarov,
  • Kruti Matawala,
  • Deep Chahodiya,
  • David Kim,
  • Mohamed Ali,
  • Jubran Al Hooti,
  • Hritvik Jain,
  • David Song,
  • Seth Goldbarg

摘要

Introduction

Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure (HF), but their effect on arrhythmias is less clear. Patients with implantable cardioverter-defibrillators (ICDs) are a high risk population for ventricular arrhythmias. However, the effects of SGLT2 inhibitors on ventricular arrhythmias remains a source of debate.

Methods

We systematically searched PubMed, Scopus, and Cochrane databases from inception to August 19, 2025, for studies evaluating SGLT2 inhibitors and arrhythmic/cardiovascular outcomes. Pooled mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model.

Results

A total of 1,605 patients were included in our analysis. SGLT2 inhibitors was associated with a significant reduction in the risk of ventricular arrhythmia (RR: 0.38; 95% CI: 0.17 to 0.81; p = 0.01), ventricular tachycardia (RR: 0.60; 95% CI: 0.41 to 0.88; p = 0.009), and supraventricular tachycardia (RR: 0.67; 95% CI: 0.47 to 0.95; p = 0.02). No significant effect was observed on non-sustained VT (RR: 0.94; 95% CI: 0.52 to 1.67; p = 0.83). However, SGLT2 inhibitors were also associated with a significant reduction in ICD shocks (RR: 0.49; 95% CI: 0.38 to 0.64; p < 0.00001) and cardiovascular mortality (RR: 0.39; 95% CI: 0.22 to 0.70; p = 0.002).

Conclusion

In ICD patients, SGLT2 inhibitor therapy significantly reduced ventricular arrhythmias, discrete sustained VT, and SVT, with secondary analyses suggesting fewer ICD shocks and reduction in CV mortality in the patients with ICD.